HLS Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-12.43	-19.66	-27.53	-23.6	-13.12
Depreciation & Amortization	21.82	22.72	31.94	34.4	30.26
Stock-Based Compensation	1.91	1.62	-0.54	2.92	2.35
Other Adjustments	1.1	2.18	6.88	1.67	-0.05
Changes in Other Operating Activities	4.73	1.14	5.04	1.55	-3.02
Operating Cash Flow	17.13	8	15.79	16.94	16.43
Operating Cash Flow Growth	114.05%	-49.31%	-6.81%	3.12%	75.82%
Capital Expenditures	-0.21	-0.02	-0.04	-0.05	-0.05
Purchases of Intangible Assets	-1.5	-	-0.15	-0.1	-0.64
Payments for Business Acquisitions	-	-1.5	-	-10	-3.82
Proceeds from Business Divestments	-	13.25	-	-	-
Investing Cash Flow	-1.7	11.74	-0.19	-10.15	-4.51
Long-Term Debt Issued	57.24	-	-	10	-
Long-Term Debt Repaid	74.99	21.04	8.86	9.78	10.5
Net Long-Term Debt Issued (Repaid)	132.23	21.04	8.86	19.78	10.5
Issuance of Common Stock	-	-	0.13	0.18	4.91
Repurchase of Common Stock	1.8	0.6	1.55	1	0.05
Net Common Stock Issued (Repurchased)	1.8	0.6	1.69	1.18	4.96
Common Dividends Paid	-	-	-2.4	-4.96	-5.12
Other Financing Activities	-2	-1.72	-1.97	-1.3	-0.64
Financing Cash Flow	-21.56	-23.36	-14.64	-6.86	-11.4
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.4	-0.87	0.27	-0.39	0.05
Net Cash Flow	-6.13	-3.63	0.96	-0.06	0.52
Free Cash Flow	16.93	7.99	15.75	16.9	16.38
Free Cash Flow Growth	111.88%	-49.28%	-6.80%	3.14%	76.00%
FCF Margin	30.50%	14.11%	24.97%	27.49%	27.30%
Free Cash Flow Per Share	0.54	0.25	0.49	0.52	0.51
Levered Free Cash Flow	146.14	25.23	18.26	32.08	24.58
Unlevered Free Cash Flow	21.05	17.17	20.53	17.32	20.03

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.